Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 1, pp 35–42 | Cite as

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

  • Zacharenia Saridaki
  • Nikolaos Malamos
  • Panagiotis Kourakos
  • Aristides Polyzos
  • Alexandros Ardavanis
  • Nikolaos Androulakis
  • Kostas Kalbakis
  • Lambros Vamvakas
  • Vassilis Georgoulias
  • Dimitris MavroudisEmail author
Original Article

Abstract

Purpose

To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC).

Patients and methods

Escalated doses of oral metronomic vinorelbine (starting dose 30 mg) every other day continuously and capecitabine (starting dose 800 mg/m2 bid) on days 1–14 every 21 days were administered. DLTs were evaluated during the first cycle.

Results

Thirty-six women were enrolled at eight escalating dose levels. For twenty-four patients, treatment was first line, for eight second line, and for four third line. The DLT level was reached at oral metronomic vinorelbine 70 mg and capecitabine 1,250 mg/m2, and the recommended MTD doses are vinorelbine 60 mg and capecitabine 1,250 mg/m2. DLTs were febrile neutropenia grade 3 and 4, diarrhea grade 4, and treatment delays due to unresolved neutropenia. There was no treatment-related death. The main toxicities were grade 2–3 neutropenia in 16.6% of patients each, grade 2–3 anemia 16.5%, grade 2–4 fatigue 27.5%, grade 2–3 nausea/vomiting 11%, and grade 3–4 diarrhea 8.2%. Two complete and 10 partial responses were documented.

Conclusion

Oral metronomic vinorelbine with capecitabine is a well-tolerated and feasible regimen that merits further evaluation in MBC.

Keywords

Metronomic vinorelbine Capecitabine Phase I Metastatic breast cancer 

Notes

Conflict of interest

None.

References

  1. 1.
    Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54:431–450PubMedGoogle Scholar
  2. 2.
    Scharovsky OG, Mainetti LE, Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16:7–15PubMedCrossRefGoogle Scholar
  3. 3.
    Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454–6461Google Scholar
  4. 4.
    Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047PubMedCrossRefGoogle Scholar
  5. 5.
    Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436PubMedCrossRefGoogle Scholar
  6. 6.
    Hobson B, Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49:405–413PubMedCrossRefGoogle Scholar
  7. 7.
    Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMedGoogle Scholar
  8. 8.
    Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232–238PubMedCrossRefGoogle Scholar
  9. 9.
    Lam T, Hetherington JW, Greenman J, Maraveyas A (2006) From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 17:113–121PubMedCrossRefGoogle Scholar
  10. 10.
    Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594–2601PubMedCrossRefGoogle Scholar
  11. 11.
    Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643–1649PubMedCrossRefGoogle Scholar
  12. 12.
    Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292PubMedCrossRefGoogle Scholar
  13. 13.
    Jones A, O’Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65:755–763PubMedCrossRefGoogle Scholar
  14. 14.
    Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O’Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567–2574PubMedGoogle Scholar
  15. 15.
    Welt A, von MG, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U (2005) Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16:64–69PubMedCrossRefGoogle Scholar
  16. 16.
    Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35–40PubMedGoogle Scholar
  17. 17.
    Addeo R, Faiola V, Cannamo G, Guarrasi R, Montella L, Lodice P, Sgambato A, Capasso E, Caraglia M, Del Prete S (2009) A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: a phase II trial. J Clin Oncol 27:15s (abstract 1085)Google Scholar
  18. 18.
    Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221–231PubMedCrossRefGoogle Scholar
  19. 19.
    Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297PubMedCrossRefGoogle Scholar
  20. 20.
    Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56–64PubMedCrossRefGoogle Scholar
  21. 21.
    Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 24:570 (abstract 570)Google Scholar
  22. 22.
    Sawada N, Fujimoto-Ouch F, Ishikawa T, Tanaka Y, Ishituka H (2002) Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 43:1088 (abstract 5388)Google Scholar
  23. 23.
    Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland SP (2007) Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer. Asia Pac J Clin Oncol 3:37–43CrossRefGoogle Scholar
  24. 24.
    Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J (2006) Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26:2451–2456PubMedGoogle Scholar
  25. 25.
    Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A (2006) Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17:322–329PubMedCrossRefGoogle Scholar
  26. 26.
    Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A (2009) Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64:673–680PubMedCrossRefGoogle Scholar
  27. 27.
    Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS (1994) Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12:1754–1763PubMedGoogle Scholar
  28. 28.
    Markman M (2005) ‘Flat-fixed dosing’ of chemotherapy: a concept whose time has come? Curr Oncol Rep 7:1–2PubMedCrossRefGoogle Scholar
  29. 29.
    National Cancer Institute (2003) Common toxicity criteria Vs 3.0Google Scholar
  30. 30.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  31. 31.
    Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110–115PubMedGoogle Scholar
  32. 32.
    Early Breast Cancer Trialists’ Collaorative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  33. 33.
    Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, CD003372Google Scholar
  34. 34.
    Wilcken N, Dear R (2008) Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000–2007. Eur J Cancer 44:2218–2225PubMedCrossRefGoogle Scholar
  35. 35.
    Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439–3460PubMedGoogle Scholar
  36. 36.
    Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174–1181PubMedCrossRefGoogle Scholar
  37. 37.
    Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–286PubMedCrossRefGoogle Scholar
  38. 38.
    Schott AF, Lew D, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Linden HM, Hortobagyi GN, Livingston RB (2010) Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). J Clin Oncol 28:15s (abstract 1006)Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Zacharenia Saridaki
    • 1
  • Nikolaos Malamos
    • 1
  • Panagiotis Kourakos
    • 1
  • Aristides Polyzos
    • 1
  • Alexandros Ardavanis
    • 1
  • Nikolaos Androulakis
    • 1
  • Kostas Kalbakis
    • 1
  • Lambros Vamvakas
    • 1
  • Vassilis Georgoulias
    • 1
  • Dimitris Mavroudis
    • 1
    Email author
  1. 1.Hellenic Oncology Research Group (HORG)AthensGreece

Personalised recommendations